- About Drugfield
METAFIZIN® 525mg TABLETS
(500MG SULPHAMETHOXYPYRAZINE +25MG PYRIMETHAMINE)
Each Metafizin® Tablet 525mg contains sulphamethoxypryazine 500mg and Pyrimethamine 25mg.
Metafizin® Tablet is indicated in the treatment of malaria caused by Plasmodium falciparum, plasmodium vivax, P. Malariae and P. Ovale.
Metafizin® contains Sulphamethoxypyrazine and Pyrimethamine which act at different points of the metabolic pathway of the parasite. Sulphamethoxpyrazine prevents the synthesis of dihydropteroate, an intermediate in dihydrofolate formation, by inhibiting the enzyme dihydropteroate synthetase while pyrimethamine inhibits the conversion of dihydrofolic acid into tetrahydrofolic acid a reaction reaction catalyzed by the enzyme dihydrofolic reductase. The tetrahydrofolic acid is the coenzyme that acts as an acceptor of a variety of one carbon unit and participates in several metabolic reactions. This type of impairment of the parasite's metabolism is termed sequential blockade.
DOSAGE AND ADMINISTRATION:
Adults: 2 tablets as a single dose, 3 tablets for adults over 70kg body weight.
Children: 5-9 years ½ - 1 tablet
10-14 years 1 - 2 tablets
Over 14 years 2 tablets
Under 5 years 25mg/kg body weight (with reference to Sulphamethoxypyrazine) in one single dose
Antimalaria prophylaxis: Half the therapeutic dose should be administered weekly according to the age of the patient.
* Metafizin® is contra-indicated in patients with marked damage of the hepatic parenchyma, severe renal insufficiency or blood dyscrasis. Patients who are hypersensitive to Sulphonamide or Pyrimethamine.
* Metafizin® is contraindicated in pregnant women during the last two weeks of pregnancy or in infants during the first two weeks of life.
Metafizin® is well tolerated at the recommended doses. Nausea and vomiting are seldom reported. Haematological anomalies e.g. thrombocytopenia, purpura, leukopenia, neutropenia and agranulocytosis must be taken into consideration because of the Sulphonamide constituent. This condition is reversible if the treatment ceases. This is common in elderly patients.
Metafizin® tablets should be administered in pregnant women under strict medical supervision. If a cutaneous erythema appears, stop treatment immediately.
KEEP OUT OF THE REACH OF CHILDREN
Symptoms of overdosage include vomiting, nausea, visual and mental disorders, purpura
and jaundice. Treatment is symptomatic and includes forced diuresis, gastric lavage which
should be carried out as early as possible.
Store in a cool dry place, protect from light.
Strips of 2 tablets in a box.
NAFDAC REGISTRATION NUMBER: 04-4745
DRUGFILED PHARMACEUTICALS LIMITED
Lynson Chemical Avenue,
Km 38 Lagos-Abeokuta Expressway,